Skip to main content

Table 5 Genotypic distribution of patients who underwent photodynamic therapy

From: Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy

Gene

Variant

Major allele (M)

Minor allele (m)

Proportion of PDT

OR (95% CI)*

P – value**

MM

Mm

mm

CFH

rs800292

G

A

9 (20.0%)/45

3 (6.5%)/46

2 (50.0%)/4

0.72 (0.24–2.17)

0.555

CFH

rs1061170

T

C

12 (14.8%)/81

2 (15.4%)/13

0 (0.0%)/1

0.56 (0.10–3.02)

0.498

C2

rs9332739

G

C

14 (15.1%)/93

0 (0.0%)/1

0 (0.0%)/1

< 0.001 (NA)

0.999

CFB

rs641153

G

A

12 (15.2%)/79

1 (7.1%)/14

0 / 0

0.31 (0.03–3.00)

0.312

SKIV2L

rs429608

G

A

13 (16.3%)/80

1 (7.7%)/13

0 (0.0%)/1

0.30 (0.03–2.69)

0.283

VEGFA

rs699947

C

A

3 (6.7%)/45

8 (20.5%)/39

3 (30.0%)/10

3.02 (1.19–7.68)

0.020

VEGFA

rs3025039

C

T

7 (13.2%)/53

6 (16.7%)/36

1 (16.7%)/6

1.22 (0.46–3.24)

0.697

ARMS2

rs10490924

T

G

8 (19.0%)/42

5 (12.5%)/40

1 (8.3%)/12

0.40 (0.14–1.15)

0.090

HTRA1

rs11200638

A

G

7 (16.7%)/42

6 (14.6%)/41

1 (8.3%)/12

0.48 (0.17–1.33)

0.155

PEDF

rs1136287

T

C

3 (13.0%)/23

7 (14.0%)/50

4 (18.2%)/22

1.39 (0.55–3.48)

0.484

  1. Among 95 patients who completed 12-month follow-up, 14 underwent photodynamic therapy and their distributions according to the genotypes of candidate polymorphisms are shown
  2. PDT Photodynamic therapy, MM Major allele homozygote, Mm Heterozygote, mm Minor allele homozygote, OR Odds ratio, CI Confidence interval, NA Not applicable
  3. *Odds ratio for minor allele under additive genetic model
  4. **P - value from logistic regression model, uncorrected for multiple testing